JCJoanna Chrzanowska

Joanna Chrzanowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanna Chrzanowska has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endocrinopathies in Inherited Leukodystrophies: A Scoping Review of Reported Frequencies, Diagnostic Strategies, and Treatment

    by Kinga Brawańska-Maśluch, Katarzyna Paliszek-Saładyga, Małgorzata Bukowska, Paulina Dziewierz, Joanna Chrzanowska, Daniel Fichte, Aleksander Basiak, Robert Śmigiel

    Leukodystrophies are a diverse group of inherited disorders affecting central nervous system white matter, with onset from infancy to adulthood. Although neurological symptoms dominate, endocrine dysfunctions are increasingly recognized as significant contributors to disease course. These can arise directly from genetic mutations or secondarily due to hypothalamic–pituitary or peripheral gland involvement. This scoping review focuses on leukodystrophies associated with hormonal abnormalities, summarizing current diagnostic approaches, preventive strategies, and treatment options. Literature from PubMed/MEDLINE and Embase (1991–May 2026) was analysed, including original research, reviews, meta-analyses, and case reports. Endocrinopathies commonly observed include adrenal insufficiency, hypogonadism, growth hormone deficiency, hypothyroidism, and diabetes mellitus. Disorders such as X-linked adrenoleukodystrophy, POLR3-related leukodystrophy, vanishing white matter disease, and Aicardi–Goutières syndrome show distinct hormonal involvement patterns. Early detection and timely hormone replacement can improve growth, development, metabolic stability, and quality of life, while preventing severe complications. Diagnosis integrates clinical evaluation, hormonal testing, neuroimaging, and advanced molecular analyses, including whole-exome or whole-genome sequencing. Effective management requires a multidisciplinary approach combining supportive care, endocrine replacement, and selected disease-modifying therapies. Understanding the interplay between neurological and endocrine features is crucial for optimizing care and improving long-term outcomes.

  • Open Access

    Complex mosaic form of trisomy chromosome 18 and monosomy chromosome X in a girl with esophageal atresia and mild developmental delay: Diagnostic and therapeutic challenge and a review of literature

    by Joanna Chrzanowska, Aleksandra Oparska, Agata Wróblewska, Krzysztof Ciucias, Maria Luboinska-Cebula, Robert Stanisław Śmigiel, Beata Wikiera

    The coexistence of mosaic trisomy 18 and Turner syndrome represents an extremely rare genetic constellation, with only a few cases reported in the literature to date. We present the case of a 7-year-old girl with esophageal atresia, full trisomy 18 in lymphocytes, and mosaic copy number changes involving trisomy 18 with coexisting monosomy X in fibroblasts, suggesting the presence of additional cell populations lacking trisomy 18. In addition, we provide a review of the relevant literature. This case is of particular clinical significance, as it describes long-term survival in a child with Edwards syndrome and illustrates the diagnostic challenges associated with tissue-limited mosaicism. Furthermore, it underscores that an established diagnosis of one genetic disorder does not preclude the coexistence of another, particularly when the clinical phenotype deviates from the classical presentation of the primary syndrome. Adequate analysis of a sufficient number of metaphases in karyotyping is essential to reliably detect or exclude mosaicism in Edwards syndrome, as the distinction between full and mosaic trisomy 18 carries important prognostic implications.

  • Pituitary Magnetic Resonance Imaging as a Prognostic Factor of Pituitary Insufficiency—The Follow‐Up Analysis of a Cohort of Children With Pituitary Stalk Interruption Syndrome

    by Joanna Chrzanowska, Jagoda Jacków‐Nowicka, Aleksandra Bodetko, Wojciech Szlasa, Monika Seifert, Agnieszka Zubkiewicz‐Kucharska, Robert Śmigiel, Joanna Bladowska

    Background: Patients diagnosed with pituitary stalk interruption syndrome (PSIS) exhibit heterogeneous endocrinological and radiological presentations. Objective: The aim of this study was to assess the correlation between MRI features in children with PSIS and their pituitary hormonal profile, and answer the question whether pituitary MRI can serve as a prognostic factor of pituitary insufficiency. Design and Patients: The study included 50 children diagnosed with PSIS. Hormonal data were collected at the first and most recent visits; with a median follow‐up of 5.9 years. Data collected before 2016 were retrospective; thereafter, prospective. Results: At initial diagnosis, 32 patients (64%) presented with isolated pituitary hormone deficiencies. During follow‐up, 15 of them (47%) developed additional deficits, increasing the prevalence of combined pituitary hormone deficiency (CPHD) from 16 (32%) to 31 patients (62%). In the remaining 17 patients (34%), only the initial isolated growth hormone deficiency (GHD) diagnosis persisted. Progression to CPHD occurred in 87.5% of patients with stalk agenesis compared to 33.3% with stalk hypoplasia ( p = 0.013). All cases of arginine vasopressin deficiency (AVPD) were observed exclusively in patients with the absence of the posterior pituitary (Fisher's exact test, p < 0.000001; odds ratio = 0, with 95% CI: 0–0.04). Furthermore, the presence of optic nerve hypoplasia (ONH) was strongly associated with the development of CPHD. Conclusions: Children with PSIS require repeated reassessment of pituitary function if CPHD is not present at the initial evaluation, as progression to complete pituitary insufficiency may occur over time. The absence of the pituitary stalk may serve as a sensitive marker of CPHD, whereas the absence of the posterior pituitary appears to predispose patients to AVPD. Additionally, the coexistence of ONH and PSIS may be associated with greater severity of anterior pituitary hormonal dysfunction. Patients who do not develop CPHD typically present with growth failure as the main manifestation, along with pituitary stalk hypoplasia and partial GHD.


  • Open Access

    Can Serum Salusin-α and Salusin-β Serve as Biomarkers for Early Atherosclerotic Lesions in Obese Children?

    by Anna Medyńska, Joanna Chrzanowska, Monika Seifert, Danuta Zwolińska

    Obesity increases the risk of atherosclerosis. Recent studies highlight the role of salusins, bioactive peptides, in its development. This study aimed to determine the risk factors for premature atherosclerosis in obese children based on obesity severity and assess the usefulness of serum salusin-α and salusin-β as early biomarkers. We examined 125 children with simple obesity, divided into two subgroups by BMI-SDS (I: 2–4, II: >4), and we compared them with 33 healthy-weight peers. Obese children had significantly higher serum salusin-α and salusin-β levels, as well as hsCRP, TG, SBP, DBP, and PWV, compared to controls. Only salusin-α levels increased with obesity severity. Salusin-α correlated with BMI SDS and hsCRP, while salusin-β showed no associations. Our findings suggest that salusin-α could be an early inflammation marker and a predictor of atherosclerosis, pointing to salusin-α, rather than salusin-β, as the earliest marker of atherosclerosis in obese children. Further research is needed to confirm these results.


  • Open Access

    Case Report: The long-term effects of the empagliflozin therapy on glycemia and renal function in a patient with Rabson-Mendenhall syndrome caused by two heterozygous variants in INSR gene

    by Joanna Chrzanowska, Julia Lachowska, Maja Weimann, Agnieszka Zubkiewicz-Kucharska, Konstancja Fornalczyk, Katarzyna Kilis-Pstrusińska, Robert Smigiel

    We present a patient with Rabson-Mendenhall syndrome with unsatisfactory glycemic control of diabetes despite the use of metformin, pioglitazone, and sitagliptin. We investigated the long-term effects of treatment with an empagliflozin. After one year of empagliflozin therapy, an improvement in metabolic control of diabetes was detected. However, eleven months after implementation of empagliflozin, the patient was diagnosed with an early form of nephrocalcinosis. The empagliflozin dose was reduced, maintaining metabolic control and reducing hypercalciuria. We discuss the probable causes of nephrocalcinosis as well as the potential impact of SGLT-2 inhibitor therapy on the occurrence and progression of renal calcium deposition.


  • Open Access

    Rare causes of congenital adrenal steroidogenesis disorders presenting in the neonatal period: clinical picture, diagnostic challenges, and treatment – a report of three cases and a literature review

    by Bartosz Siudek, Wiktoria Bińczyk, Olgierd Dróżdż, Filip Grajnert, Jakub Plizga, Agnieszka Głuszczyk, Barbara Salmonowicz, Robert Śmigiel, Joanna Chrzanowska

    Congenital adrenal steroidogenesis disorders are rare diseases that can lead to life-threatening conditions in newborns, primarily salt-wasting syndrome and adrenal crisis. It is therefore essential for paediatricians and family physicians to be familiar with the symptoms suggestive of steroidogenesis defects, such as failure to thrive, vomiting, dehydration, electrolyte imbalances, and abnormal appearance of external genitalia. Early initiation of diagnostic procedures enables the prompt introduction of appropriate hormonal replacement therapy. However, the diagnostic process is not straightforward and requires consideration of other rare causes of the disease, which often present with similar but diverse clinical, biochemical, and hormonal features. A normal result of a screening test assessing 17-hydroxyprogesterone levels does not rule out rare causes of steroidogenesis disorders, which should be considered in the differential diagnosis when the aforementioned symptoms are present. This report discusses three newborns: one diagnosed with congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, and two with aldosterone synthase deficiency.

  • Open Access

    New Markers of Early Kidney Damage in Children and Adolescents with Simple Obesity

    by Anna Medyńska, Joanna Chrzanowska, Agnieszka Zubkiewicz-Kucharska, Danuta Zwolińska

    The impact of obesity on kidney injury and the development of chronic kidney disease (CKD) is well documented. Unfortunately, the early stages of CKD are asymptomatic, leading to a delayed diagnosis and a worse prognosis. There is a need for more sensitive indicators of kidney damage than those currently used. We aimed to assess the usefulness of serum t-CAF, urinary netrin-1, α-GST, π-GST, calbindin, and calprotectin as biomarkers of early kidney damage in obese children and to investigate the relationship between these indicators and the degree of obesity. A total of 125 simple obese, normoalbuminuric children and 33 non-obese children as controls were selected. Patients were divided into 2 subgroups according to SDS BMI (I: 2 ≤ 4, II: >4). Serum t-CAF was significantly higher in the obese group compared to the controls, as were urinary α-GST, netrin-1, π-GST, and calprotectin. No difference was found between the two obese groups. In normoalbuminuric obese children and adolescents without significant metabolic disorders, serum t-CAF may be a new biomarker for the early detection of renal dysfunction, and urinary netrin-1, α-GST, π-GST, and calprotectin may be better indicators for the detection of early tubular damage, independent of the severity of obesity.


  • Open Access

    Further Delineation of Clinical Phenotype of ZMYND11 Variants in Patients with Neurodevelopmental Dysmorphic Syndrome

    by Aleksandra Bodetko, Joanna Chrzanowska, Malgorzata Rydzanicz, Agnieszka Borys-Iwanicka, Pawel Karpinski, Joanna Bladowska, Rafal Ploski, Robert Smigiel

    Intellectual disability with speech delay and behavioural abnormalities, as well as hypotonia, seizures, feeding difficulties and craniofacial dysmorphism, are the main symptoms associated with pathogenic variants of the ZMYND11 gene. The range of clinical manifestations of the ZMYND phenotype is constantly being expanded by new cases described in the literature. Here, we present two previously unreported paediatric patients with neurodevelopmental challenges, who were diagnosed with missense variants in the ZMYND11 gene. It should be noted that one of the individuals manifested with hyperinsulinaemic hypoglycaemia (HH), a symptom that was not described before in published works. The reason for the occurrence of HH in our proband is not clear, so we try to explain the origin of this symptom in the context of the ZMYND11 syndrome. Thus, this paper contributes to knowledge on the range of possible manifestations of the ZMYND disease and provides further evidence supporting its association with neurodevelopmental challenges.


  • Open Access

    Further Delineation of Clinical Phenotype of ZMYND11 Variants in Patients with Neurodevelopmental Dysmorphic Syndrome and Hyperinsulinemic Hypoglycemia

    by Aleksandra Maria Bodetko, Joanna Chrzanowska, Malgorzata Rydzanicz, Agnieszka Borys-Iwanicka, Pawel Karpinski, Joanna Bladowska, Rafal Ploski, Robert Smigiel

    Intellectual disability with speech delay and behavioural abnormalities as well as hypotonia, seizures, feeding difficulties and cra-niofacial dysmorphism are the main symptoms associated with pathogenic variants of ZMYND11 gene. The range of clinical mani-festations of ZMYND phenotype is constantly being expanded by new cases described in the literature. Here, we present 2 previ-ously unreported paediatric patients with neurodevelopmental features diagnosed with missense variants in ZMYND11 gene. It should be noted that one of the individuals manifested with hyperinsulinemic hypoglycaemia (HH), a symptom that was not de-scribed before in published works. Although the reason for the occurrence of HH in our proband is not clear, it is likely that it broadens the spectrum of symptoms characteristic of ZMYND11 syndrome. Thus, this paper contributes to extending the range of possible manifestations of ZMYND disease and further supports its association with neurodevelopmental challenges.


  • Open Access

    Foot drop in children with newly diagnosed type 1 diabetes: three case reports

    by Joanna Chrzanowska, Monika Seifert, Barbara Salmonowicz, Agnieszka Zubkiewicz-Kucharska

    Summary The etiology of foot drop is diverse from various diseases to mechanic injuries and includes neuropathy of the peroneal nerve. Peroneal neuropathy might also be one of the forms of diabetic neuropathy, very rarely reported as the first sign of diabetes. We describe three cases of children with newly diagnosed type 1 diabetes (TID) who developed unilateral peroneal nerve palsies and tibial nerve palsies, presenting clinically as a foot drop. In two of our cases, the symptoms of foot drop occurred shortly after starting treatment for severe diabetes ketoacidosis. In the third patient, food drop was a reason for the initial medical consultation, but eventually, TID was diagnosed. The presented cases highlight that neuropathy can be observed not only as a chronic complication of T1D, but it can also appear at the time of disease manifestation. The incorrect position of the lower limb during a keto coma may contribute to the development of neuropathy. Learning points Neuropathy can be observed not only as a chronic complication of type 1 diabetes (T1D), but it can also appear at the time of disease manifestation. The incorrect position of the lower limb causing external pressure during a keto coma may contribute to the development of neuropathy. It is important to examine the glycemia in patients with acute peroneal neuropathy, as this kind of peripheral neuropathy can be associated with newly diagnosed T1D. Normalization of glycemia might lead to rapid neuronal recovery. Abstract Summary The etiology of foot drop is diverse from various diseases to mechanic injuries and includes neuropathy of the peroneal nerve. Peroneal neuropathy might also be one of the forms of diabetic neuropathy, very rarely reported as the first sign of diabetes. We describe three cases of children with newly diagnosed type 1 diabetes (TID) who developed unilateral peroneal nerve palsies and tibial nerve palsies, presenting clinically as a foot drop. In two of our cases, the symptoms of foot drop occurred shortly after starting treatment for severe diabetes ketoacidosis. In the third patient, food drop was a reason for the initial medical consultation, but eventually, TID was diagnosed. The presented cases highlight that neuropathy can be observed not only as a chronic complication of T1D, but it can also appear at the time of disease manifestation. The incorrect position of the lower limb during a keto coma may contribute to the development of neuropathy. Learning points Neuropathy can be observed not only as a chronic complication of type 1 diabetes (T1D), but it can also appear at the time of disease manifestation. The incorrect position of the lower limb causing external pressure during a keto coma may contribute to the development of neuropathy. It is important to examine the glycemia in patients with acute peroneal neuropathy, as this kind of peripheral neuropathy can be associated with newly diagnosed T1D. Normalization of glycemia might lead to rapid neuronal recovery.